Search…
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Search...
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Home
>
Latest
Lates News
15/07/2025
Coca-Cola India appoints new CEO.
Latest
4 m ago
Chinese biopharmaceutical company announced on July 15 that it will acquire 95.09% of the equity of Shanghai Lixin Pharmaceutical for a total price of about $500 million. In addition to the 4.91% equity acquired during Lixin's previous round of financing, Lixin Pharmaceutical will become a wholly-owned subsidiary of Chinese biopharmaceutical company after the transaction is completed. There have been market rumors that the authorization agreement reached between Lixin and Merck for the PD-1/VEGF bispecific antibody LM-299 has been "returned". In response, Chinese biopharmaceutical company stated that the cooperation between Lixin and Merck is progressing in an orderly manner according to the licensing agreement. "Currently, we are advancing technology transfer, and after completing the technology transfer according to the transaction contract, Lixin will receive a $300 million milestone payment for the technology transfer. According to a previous press release by Merck, it is expected that this technology transfer will be completed by 2025," Chinese biopharmaceutical company stated.
4 m ago
Chinese biopharmaceutical company responds to rumors of "returned goods": Merck's cooperation with Lee Xin is progressing positively and proceeding normally and orderly.
4 m ago
Nvidia's holding of CoreWeave continues to rise, with a recent surge of 10%. The company plans to invest up to $6 billion in building a large AI data center in the United States.
4 m ago
Abnormal movement in the US stock market | Resumed shipments to China, AMD (AMD.US) and Nvidia (NVDA.US) both rose at the opening bell.
5 m ago
Citigroup's traders achieved their best second-quarter performance in five years, taking advantage of market volatility caused by tariffs. Quarterly revenue benefited from record trading volumes. The bank's fixed income trading revenue surged 20% to $4.3 billion, surpassing analysts' expectations of $3.9 billion. Citigroup's stock trading revenue reached $1.6 billion, also exceeding expectations. Since President Donald Trump announced a series of tariffs on global trade partners in April, global market volatility has intensified. This has been good news for Citigroup and its Wall Street peers' trading departments, as increased client activity has brought in revenue, but it has also disrupted plans for a strong recovery in mergers and acquisitions. Earlier on Tuesday, JPMorgan Chase also reported trading revenues that surpassed analysts' expectations. The bank's fixed income trading department achieved revenues of $5.69 billion, a 14% increase from the same period last year. The bank credited this growth to its foreign exchange and emerging markets team, as well as its interest rate and commodities business. "We are enhancing the performance of each business division to capture market share and drive higher returns," said Citigroup CEO Jane Fraser in a statement.
See all latest
